LNDC Landec Corp.

Landec Corporation Sets Second Quarter 2021 Earnings Conference Call for January 6, 2021 at 2 p.m. PT

Landec Corporation Sets Second Quarter 2021 Earnings Conference Call for January 6, 2021 at 2 p.m. PT

SANTA MARIA, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Landec Corporation (Nasdaq: LNDC), a diversified health and wellness company with two operating businesses, Curation Foods, Inc. and Lifecore Biomedical, Inc., will hold a conference call on Wednesday, January 6, 2021 at 2 p.m. Pacific time to discuss its results for the fiscal second quarter 2021. Financial results will be reported for the 2021 fiscal second quarter ended November 29, 2020 after market close on January 6, 2021.

Landec's President and CEO, Dr. Albert Bolles, will host the Conference Call with Brian McLaughlin, Chief Financial Officer and Jim Hall, Lifecore President. A question and answer period will follow the presentation.

Date: Wednesday, January 6, 2021

Time: 2 p.m. Pacific time (5 p.m. Eastern time)

Toll Free Participant Dial-in Number: 1-877-407-3982

U.S. and International Toll Number: 1-201-493-6780

Conference ID: 13714051

Webcast:

The webcast will be available for 30 days through February 6, 2021.

A replay of the teleconference will be available for one week until midnight Eastern Time on Wednesday, January 13, 2021.

Toll free replay dial in: 1-844-512-2921

International replay: 1-412-317-6671

Replay passcode: 13714051

About Landec Corporation



Landec Corporation (NASDAQ: LNDC) is a leading innovator of diversified health and wellness solutions with two operating businesses: Curation Foods, Inc. and Lifecore Biomedical, Inc. Landec designs, develops, manufactures, and sells products for the food and biopharmaceutical industry. Curation Foods is focused on innovating and distributing plant-based foods with 100% clean ingredients to retail, club and foodservice channels throughout North America. Curation Foods is able to maximize product freshness through its geographically dispersed family of growers, refrigerated supply chain and patented BreatheWay® packaging technology. Curation Foods brands include Eat Smart® fresh packaged vegetables and salads, O Olive Oil & Vinegar® premium artisan products, and Yucatan® and Cabo Fresh® avocado products. Lifecore Biomedical is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile, injectable pharmaceutical products in syringes and vials. As a leading manufacturer of premium, injectable grade Hyaluronic Acid, Lifecore brings 35 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the Company, visit Landec’s website at .

Contact Information:      

Investor Relations:

Jeff Sonnek

(646) 277-1263



EN
22/12/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Landec Corp.

 PRESS RELEASE

Lifecore Biomedical to Participate at 24th Annual Contract Pharma Cont...

Lifecore Biomedical to Participate at 24th Annual Contract Pharma Contracting and Outsourcing Conference CHASKA, Minn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 24th Annual Contract Pharma Contracting and Outsourcing Conference. Recognized as one of the top annual events for pharmaceutical outsourcing and contract manufacturing, the Contract Pharma conference will take place September 18-19, 2025, in New Brun...

 PRESS RELEASE

Lifecore Biomedical to Participate in Upcoming Investor Conferences

Lifecore Biomedical to Participate in Upcoming Investor Conferences CHASKA, Minn., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in multiple upcoming investor conferences. Details regarding Lifecore’s participation are as follows: Morgan Stanley 23rd Annual Global Healthcare ConferenceDetails: Lifecore management will participate in a fireside chat and in investor meetingsConference Dates: September 8-10, 2025Fireside...

 PRESS RELEASE

Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financ...

Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update -- Recorded $128.9 Million in Fiscal 2025 Revenue, Meeting Full-Year Guidance; Maintains Commitment to Mid-Term Outlook -- -- Nine New Programs Signed with New Customers During Fiscal 2025, Reflecting Growth into Modalities Beyond the Company's Traditional Area of Strength in Ophthalmic Therapeutics -- -- Improved Efficiency and Productivity Across the Organization -- Conference Call Today at 4:30pm ET CHASKA, Minn., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, In...

 PRESS RELEASE

Lifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Fina...

Lifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Financial Results on August 7, 2025 Webcast Scheduled for Thursday, August 7 at 4:30 p.m. Eastern CHASKA, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the fourth quarter and fiscal year 2025 on Thursday, August 7, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore’s senior management team will host a webcast ...

 PRESS RELEASE

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHASKA, Minn., July 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on July 11, 2025, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate of 6,338 shares of its common stock and stock options for an aggregate of 29,575 shares of common sto...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch